Nortriptyline chemical structure
Find information on thousands of medical conditions and prescription drugs.

Pamelor

Nortriptyline hydrochloride is 1-Propanamine, 3-(10,11-dihydro, 5H-dibenzo cyclohepten- 5-ylidene)-N-methyl-,hydrochloride. It is a second generation tricyclic antidepressant marketed under the tradenames Aventyl® and Pamelor®. It is used in the treatment of depression and childhood nocturnal enuresis (bedwetting). In addition it is sometimes used for chronic pain modification. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Morning-after pill
Pacerone
Paclitaxel
Pamelor
Pancuronium bromide
Panheprin
Panthenol
Pantoprazole
Paracetamol
Parahexal
Parnate
Paroxetine
Patanol
Pavulon
Paxil
PCE
Pemetrexed
Pemoline
Penhexal VK
Penicillamine
Penicillinase
Pentaerithrityl tetranitrate
Pentagastrin
Pentamidine
Pentasa
Pentazocine
Pentobarbital
Pentosan polysulfate sodium
Pentostatin
Pentothal
Pentoxifylline
Percocet
Percodan
Pergolide
Pergonal
Perhexiline
Peridex
Periochip
Periogard
Periostat
Permapen
Permethrin
Permitil
Perphenazine
Pethidine
Pfizerpen
Phenacetin
Phenazine
Phenazone
Phenazopyridine
Phencyclidine
Phendimetrazine
Phenelzine
Phenergan
Phenmetrazine
Phenobarbital
Phenolphthalein
Phenothiazine
Phenoxybenzamine
Phenprobamate
Phentermine
Phentolamine
Phenylalanine
Phenylbutazone
Phenylephrine
Phenylpropanolamine
Phenyltoloxamine
Phenytoin
Phrenilin
Phytomenadione
Pimozide
Pindolol
Pioglitazone
Piperacillin
Piracetam
Pirolazamide
Piroxicam
Pitocin
Placidyl
Plavix
Plenaxis
Plendil
Pletal
Polyestradiol phosphate
Polyglycolic acid
Polymox
Polysorbate
Polysorbate 80
Polysporin
Portia
Povidone
Practolol
Pramiracetam
Pramlintide
Prandase
Prasterone
Pravachol
Pravastatin
Praziquantel
Prazosin
Pseudoephedrine
Pulmicort
Puromycin
Pyrazinamide
Pyridostigmine bromide
Pyridoxine
Pyrimethamine
Pyrithione zinc
Pyritinol
ViroPharma Incorporated
Q
R
S
T
U
V
W
X
Y
Z

Clinical Pharmacology

Nortriptyline inhibits the reuptake of norepinephrine (noradrenalin) and, to a lesser extent, serotonin. Operant conditioning techniques in rats and pigeons suggest that nortriptyline has a combination of stimulant and depressant properties.

Indications

FDA-approved for treatment of depressive disorders. In UK also may be used for treating nocturnal enuresis with courses of treatment lasting no moer than 3 months. Also off-label used for the treatment of panic disorder, prevention of migraine headaches and chronic pain or neuralgia modification (particularly Temporomandibular joint disorder).

Metabolism

Nortriptyline is metabolised in the liver by hepatic enzyme CYP2D6. Approximately 7 to 10 percent of caucasians are poor metabolisers and might experience more adverse effects, thus, a lower dosage is often necessary in these individuals. Blood levels of nortriptyline should be obtained during long term treatment to avoid toxicity and optimise response.

Dosage

25 - 75mg at bedtime. The dosage may be higher or lower depending on your prescribing physician. Doses above 150 mg/day are not recommended.

Side Effects

Dry mouth, drowsiness, orthostatic hypotension, urinary retention, constipation, and rapid or irregular heartbeat. Some sexual side effects may be a problem as well. Less commonly, seizures and ECG/EKG changes have been reported, especially in overdose. However, the incidence of side effects with nortriptyline is somewhat lower than with the first generation tricyclics (e.g. imipramine (Tofranil®), amitriptyline (Elavil®)).

Warnings

Persons with a history of cardiovascular disease, stroke, glaucoma and/or seizures should be given nortriptyline only under close supervision as well as those who are hyperthyroid or receiving thyroid medication. Patients should be cautioned against the use of alcohol during nortriptyline therapy.

Precautions

Pregnancy and lactation. Children under the age of 18.

Contraindications

In the acute recovery phase after myocardial infarction (e.g. heart attack). Do not use MAO Inhibitors (e.g. phenelzine, tranylcypromine, etc) with nortriptyline as hyperpyretic crises, severe convulsions, and fatalities have occurred when similar tricyclic antidepressants were used in such combinations.

Do not use if you have had serious reactions to other tricyclic antidepressants unless under the close supervision of your prescribing physician.

Overdose

Deaths may occur from overdosage with tricyclic antidepressants. Serious cardiac arrhythmias and coma are also possible. Keep this medication away from infants and children in a child-proof container.

Read more at Wikipedia.org


[List your site here Free!]


How to take an antidepressant: it's no longer enough to treat depression; it's necessary to banish it. What's the best drug for that? It boils down to
From Psychology Today, 1/1/03 by Hara Estroff Marano

fifteen years ago, Prozac launched a revolution. It rendered depression a disorder that was--finally--safely treatable. The torrent of prose hailing Prozac and its chemical kin eventually made the mental illness dinner-party discourse. Today, a much quieter revolution in treatment is taking place. It, too, has its origins in Prozac and its siblings, the selective serotonin reuptake inhibitors.

Fifteen years of experience with reasonably safe treatments has given the mental health world a new understanding of the disorder and its true course: It's no longer enough to merely treat depression; it's necessary to banish it.

Increasingly, the aim of treatment is not to make patients better but to make them completely well. In the absence of full remission from an episode of depression, the disorder tends to recur. What's more, studies now show that the longer patients remain sick, the harder it is for them to recover completely.

"It became very clear over the past several years that people who don't achieve full remission are at high risk for relapse and for doing poorly," says Jonathan Alpert, M.D., Ph.D., associate director of the depression research program at Massachusetts General Hospital in Boston. "Even if they don't have a full relapse, they don't do well in social and occupational function."

There is no magic bullet; evidence indicates that the available antidepressants are equally effective. All of the drugs get 70 percent of people better within six to ten weeks, according to David Dunner, M.D., director of the Center for Anxiety and Depression at the University of Washington. However, "better" does not necessarily mean symptom-free. "There isn't any difference among the drugs regarding that."

Where the drugs do differ, however, is in the side effects they create, especially in the long haul. Side effects have become a central consideration in the new approach to depression treatment.

Long-term treatment is also critical. Data indicate that individuals should be treated for at least nine months following their first acute episode. If they have chronic depression--an episode lasting two years or more--they need to be treated for two years after remission. "And if they have recurrent depression marked by multiple episodes, perhaps forever," notes Dunner.

However, the average duration of a prescription is about 100 days. "It's a serious problem," Dunner points out. "We're not treating people nearly long enough."

Nor is treatment aggressive enough, according to Alpert: "Really pushing for remission may mean using two antidepressants at once or pushing the close up higher than one would normally use."

Pick your pill

For many experts, the most sensible approach to selecting an antidepressant is to factor in the presence of associated or co-occurring conditions. Anxiety disorders, for example, commonly accompany depression. The selective serotonin reuptake inhibitors (SSRIs) have been well studied for the major anxiety disorders: panic, social phobia, generalized anxiety disorder and obsessive-compulsive disorder.

"For someone who has depression and social phobia, it's reasonable to use a medication whose effectiveness has been well documented for both disorders," reports Alpert. The data also suggest that SSRIs are "reasonable first choices" for those with eating disorders.

But antidepressants don't work if people don't take them. Patients have to be willing to put up with side effects that range from drowsiness to seizures. As true as that is for short-term treatment, it's even more the case with long-term treatment. "The issue is, what can we do to get these patients to stay on the drugs for the length of time the evidence now suggests is best?" explains Dunner.

In the long run, two side effects are especially bothersome: sexual dysfunction and weight gain. The SSRIs are strongly linked to sexual dysfunction in both sexes--diminished libido, erectile dysfunction and delayed, attenuated or absent orgasm. In one recent study, up to 70 percent of patients receiving the newer antidepressants reported sexual dysfunction when asked directly about it. That contradicts the 15 percent declared on product labels. Some of the atypical antidepressants--such as Wellbutrin (buproprion) and Remeron (mirtazapine)--do better at preserving sexual function.

In regard to weight gain, the SSRI antidepressants do not appear to be created equally. Paxil, for one, seems to cause more problems. One study, by Andrew Nierenberg, M.D., associate director at Massachusetts General's clinical depression and research program, showed that after six months, patients put on more weight with Paxil than with the other antidepressants. Evidence favors non-SSRIs for avoiding weight gain, particularly bupropion and Serzone (nefazodone). Nefazadone, however, bears a Food and Drug Administration warning that it can cause liver failure in rare instances.

Paxil also causes more sexual dysfunction, which leads many individuals to discontinue their regimen. Teresa* found that Paxil stanched her anxiety and depression after only two weeks. "I was calmer. My emotions weren't erupting," recalls the 55-year-old social worker. But the flip side was a sense of muted emotions and diminished sexual appetite. "The libido isn't just your sex drive, it's your passion for life," says Teresa. She plans to continue taking Paxil despite the side effects. "It did what I wanted it to do, which is take away the pain."

The bargaining table

Psychiatrists believe that side effects are a matter of negotiation. "Some of the most teary exchanges in my office have involved women who don't want to gain weight on a drug," confides John Herman, M.D., director of clinical services in psychiatry at Mass General. "The patients come in tearful because they're depressed; then they come in no longer depressed but distraught because they are way overweight."

"It's a stealth side effect," observes Jerrold Rosenbaum, M.D., chief of psychiatry at Massachusetts General. "It emerges subtly over time and surprises everybody."

Physicians must consider what is tolerable in exchange for a medication's primary effects and understand that the bar has been raised. "As the cookie lady Mrs. Fields once said, `Good enough is not good enough,'" says Dunner. "Just because a patient improves doesn't mean the treatment should be stopped."

Sometimes the problem lies with patients themselves. Often, they feel better and stop their medication, thinking it's no longer needed. "Although an individual patient might win, it's a mistake," observes Dunner. "The odds are against her."

At least as often, side effects interfere with long-term patient compliance. Therefore, clinicians must know how to manage the dosage or try to augment the antidepressant with another medication so the patient will stay on course. Psychostimulants such as Dexedrine, Ritalin and Adderall are widely used as antidepressant adjuncts, even though their primary indication is for attention deficit disorders or narcolepsy. Provigil, recently approved for the treatment of narcolepsy, is also used to boost the efficacy of antidepressants or reduce the drowsiness they cause. Thyroid hormones and natural remedies such as omega-3 fatty acids and SAM-e are also being explored.

Leading psychopharmacologists contend that antidepressant treatment can be delivered in a way that instills confidence in patients--enough to ride out early difficulties. "I try to emphasize the early side effects that might occur and how to manage them," reports Dunner. "So if a patient suffers from them, he doesn't say, `What is all this about?'"

It's also important for patients to know that taking one pill will not instantly make them better; in fact, the drugs are not likely to begin working for three to four weeks. Treatment will then progress in eight to twelve weeks.

Some 30 percent of depressed patients do not respond to the first drug they try. If there is no improvement after a patient uses a medication at an adequate dose and for an adequate duration of time, a switch is in order. A drug with a different mechanism of action may be preferred. The trial, though, isn't lost. The patient may have lost time, but valuable information has been gained.

"We're trying to get the patient over that last little hump," says Dunner. "Granted, we can improve most patients, but can we actually get them back to normal? I think we can do this with many more patients than we used to."

LEARN MORE ABOUT IT:

Night Falls Fast Kay Redfield Jamison (Vintage, 2000)

The Noonday Demon Andrew Solomon (Touchstone, 2002)

Depression and Bipolar Support Alliance: www.ndmda.org

Psychology Today: www.psychologytoday.com

American Psychological Association: www.apa.org

National Institute of Mental Health: www.nimh.nih.gov/publicat/medmenu.cfm

* Identifies have changed.

Hara Estroff Marano is the editor of Psychology Today's Blues Buster newsletter as well as editor at large of PT.

COPYRIGHT 2003 Sussex Publishers, Inc.
COPYRIGHT 2003 Gale Group

Return to Pamelor
Home Contact Resources Exchange Links ebay